Acta Dermato-Venereologica

26/11/2025

Delusional Infestation, Psychiatric Comorbidity, and Dementia: A Review of 146 Swedish Patients

Authors: Jessica Norberg, Sol-Britt Lonne-Rahm, Louise Lönndahl

Delusional infestation (DI) is a rare but severe dermatopsychiatric disorder. The personal and social impact of the disease may be substantial, as may the use of healthcare resources. This study confirms the correlation between DI and psychiatric comorbidity. Other findings, such as the mean age at presentation (60.3 years), were in consistency with previous reports, as was the female-to-male ratio of 4:1. However, DI presenting as a presumed early sign of dementia – in this study occurring in nearly 10% of all patients – is an observation to take into consideration. To our knowledge, this has previously only been described anecdotally in case reports, mainly as one symptom among others in late-stage disease. In this study, these patients initially had no obvious signs of cognitive impairment, they were older than the whole study group when first presenting with DI symptoms (mean age 79.2 years vs 60.3 years) and to a lesser extent had findings of psychiatric comorbidity (14% vs 42%). This is a reminder to the clinician: when seeing a patient with DI, it is important to look for comorbid conditions and psychiatric illnesses that should be diagnosed and treated. A patient who presents with DI symptoms at an older-than-average age, with no former history of psychiatric comorbidity, should raise the clinician’s awareness to look for signs of cognitive impairment.

https://doi.org/10.2340/actadv.v105.43823

26/11/2025

Functional Brain Imaging Reveals Reconstitution of the Central Nervous Itch Network Upon Rifampicin Therapy in Hepatic Pruritus

Authors: Marcel Vetter, Theresa Buchwald, Arnd Dörfler, Clemens Forster, Andreas E. Kremer

https://doi.org/10.2340/actadv.v105.44350

26/11/2025

Bilateral Nail Dystrophy of the Fourth Digits: A Quiz

Authors: Hanife Karataş, Elif Kaya, Müzeyyen Gönül, Selda Pelin Kartal

Clinical photo: Mild crumbling, longitudinal fissuring, and pitting of the left fourth digit.

What is your diagnosis?
1: Lichen planus of the nails
2: Onychomycosis
3: Carpal tunnel syndrome-related nail changes
4: Ischaemic nail changes due to peripheral vascular disease

See https://doi.org/10.2340/actadv.v105.44336 for answer

20/11/2025

TRPM8 Agonist (Cryosim-1) Cream for Chronic Prurigo: A Randomized, Vehicle-controlled Trial

Authors: Ji Young Um, Han Bi Kim, So Yeon Lee, Bo Young Chung, Chun Wook Park, Hye One Kim

Chronic prurigo is a skin condition that causes severe, long-lasting itching and discomfort. Many patients struggle to find safe and effective relief. This study tested a new cooling cream made from a TRPM8-activating ingredient and found that it significantly reduced itching and improved skin health without serious side effects. The cream was most effective and comfortable at a low concentration. This offers a promising new option for people suffering from chronic itch, especially those looking for non-steroid, daily-use treatments. It may improve quality of life and reduce dependence on stronger medications.

https://doi.org/10.2340/actadv.v105.44488

# skinbarrier

19/11/2025

Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study

Authors: Yajie Yu, Yanqing Chen, Yuping Zhang, Mukai Chen, Yongzhi Han, Xinsheng Chen, Lei Ling, Xueling Tan, Junping Zhao, Rongzhi Liao, Jiajun He, Danyi Huang, Juan Luo, Chen Li, Han Ma

This study is a multicentre, retrospective, observational, self-comparison real-world study. With the ageing of society, the prevalence of atopic dermatitis among the elderly is gradually increasing. Notably, pruritus stands as the most prevalent and burdensome symptom of atopic dermatitis. We aim to introduce a treatment option that provides rapid relief, is convenient to administer, and effectively alleviates itching while achieving therapeutic goals and managing potential medication-related risks for elderly patients with atopic dermatitis.

https://doi.org/10.2340/actadv.v105.44210

17/11/2025

Epidermolysis Bullosa Simplex with Mottled Pigmentation and Migratory Circinate Erythema: Distinct Subtypes or a Continuum?

Authors: Laura E. Valinotto, Mónica Natale, Silvina B. Lusso, Luz Velazquez Perdomo, Agustín Izquierdo, Romina Andrada, Eliana Cella, Juana Goitia, Maria del Carmen Boente, Maria I. Prado, Silvina de Freijo, Graciela Manzur

Epidermolysis bullosa simplex is a rare genetic skin condition. Two rare forms of epidermolysis bullosa simplex – 1 with ring-shaped red patches and another with mottled pigmentation – were thought to be separate entities. In this study, we found that both patterns can appear in people from the same family, and even in the same person, all carrying the same genetic change in the KRT5 gene. This suggests that these forms represent different stages in the progression of the disease, rather than distinct entities. Understanding this clinical presentation helps improve diagnosis and may lead to better management for people living with epidermolysis bullosa simplex.

https://doi.org/10.2340/actadv.v105.44169

17/11/2025

Successful Dose Reduction of Janus-kinase Inhibitors in Well-controlled Atopic Dermatitis: A Prospective, Multicentre, Real-world Study

Authors: Anne R. Schlösser, Anouk G.M. Caron, Merle S. den Ouden, Sara J. Baart, Louise A.A. Gerbens, Phyllis I. Spuls, Tamar E.C. Nijsten, Renske Schappin, Dirkjan Hijnen

This study looked at whether people with well-controlled eczema could safely reduce their dose of JAK1 inhibitor medication in daily practice. Sixty patients lowered their dose of abrocitinib or upadacitinib under medical supervision. After 12 weeks, 80% of them stayed on the lower dose without losing control of their disease. Some symptoms increased slightly but not enough to be considered clinically relevant. Those who returned to their original dose regained disease control. These results suggest that reducing the dose of JAK1 inhibitors is possible, which may lower the risk of side effects and decrease long-term medication use.

https://doi.org/10.2340/actadv.v105.44165

17/11/2025

🚨Spontaneous hair regrowth in alopecia areata? It's rarer than expected!
This new meta-analysis of placebo-controlled studies reveals that most patients need treatment for significant improvement.

📍Only about 8.2% of patients showed ≥30% hair regrowth without active treatment.
📍Nearly complete spontaneous regrowth (≥90%) occurred in just 1.6% of cases.
📍Earlier reports may have overestimated spontaneous recovery rates.
📍These results highlight the importance of timely and active management for alopecia areata patients.

Read more: https://lnkd.in/dmuyvv2S

13/11/2025

Acta Dermato-Venereologica Newsletter November 2025

Margin Status following Simple Excision of Head and Neck Basal Cell Carcinoma: A Population-Based, Cross-Sectional Study of 9,291 ExcisionsMilad K. Tabatabai, Johan Sieborg, Katrine E. Karmisholt, Nina L. Mårtensson, Grethe Schmidt, Emily Wenande, Merete Haedersdal

12/11/2025

Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation

Authors: Chih-Tsung Hung, Chi-Hsiang Chung, Tsu-Hsuan Weng, Chun-Teng Tsai, Wu-Chien Chien, Yung-Lung Chang

Diabetes and skin diseases like psoriasis often occur together, creating health challenges for millions worldwide. Some diabetes medications might help protect against skin problems, but previous studies presented mixed results. We studied nearly 79,000 diabetes patients over 13 years and found that those taking specific diabetes drugs had a 42% lower risk of developing psoriasis or joint problems. Different medications showed varying levels of association. Laboratory tests indicated that these drugs may reduce skin inflammation. This means doctors could choose diabetes medications that control blood sugar while possibly reducing the risk of skin diseases, though clinical trials are needed.

https://doi.org/10.2340/actadv.v105.44343

12/11/2025

Disseminated Erythema and Vesicles on the Trunk and Extremities in a Teenager: A Quiz

Authors: Chunxia Zhao, Hua Wang, Lei Wang

Clinical photo: Disseminated oedematous, urticarial erythema with vesicles and tense bullae on the trunk and upper extremities and tense vesicles and bullae exhibit a “string-of-pearls” pattern on the dorsal hand.

What is your diagnosis?
1: Epidermolysis bullosa hereditarian
2: Linear IgA bullous dermatosis (LABD)
3: Bullous systemic lupus erythematosus (BSLE)
4: Epidermolysis bullosa acquisita (EBA)

See https://doi.org/10.2340/actadv.v105.44634 for answer

12/11/2025

Efficacy and Safety of Tofacitinib in Palmoplantar Pustulosis: A Retrospective Study

Authors: Shuang Lyu, Xiaotong Xue, Na Wang, Hong Liu, Furen Zhang

Palmoplantar pustulosis is a chronic skin disease causing painful palm/sole pustules, often resistant to treatment and prone to relapse. This study shows that tofacitinib – an oral Janus kinase inhibitor – significantly improves symptoms with low side effects: 72.41 % of patients achieved a 50% lesion reduction by week 12. Averaging 12 months of follow-up, one-third maintained clearance without medication. The findings provide real-world evidence to support Janus kinase inhibitors as a safe, accessible oral option for palmoplantar pustulosis, enhancing treatment choices and guiding future research to improve patient outcomes.

https://doi.org/10.2340/actadv.v105.44083